---
layout: default
title: Nitrous Oxide
parent: 僅模型預測 (L5)
nav_order: 506
evidence_level: L5
indication_count: 1
---

# Nitrous Oxide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Nitrous Oxide: From Anesthesia/Analgesia to Benign Prostatic Hyperplasia

## One-Sentence Summary

Nitrous oxide is an inhalational anesthetic/analgesic gas long used for procedural sedation and pain control (e.g., dental, obstetric, and minor surgical procedures). The TxGNN model predicts it may be effective for **Benign Prostatic Hyperplasia (BPH)**, but this is currently supported only by **1 clinical trial** (a procedural-anxiolysis study, not a BPH-treatment trial) and **3 older case-report/technical publications**, none of which test nitrous oxide as a BPH therapy.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Anesthetic/analgesic gas (inhalational) — specific NPRA-approved indication text not captured in this evidence pack |
| Predicted New Indication | Benign Prostatic Hyperplasia |
| TxGNN Prediction Score | 99.52% |
| Evidence Level | L5 (model prediction only; the one available trial and all literature are procedural/anesthesia-related, not BPH-treatment evidence) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for nitrous oxide in this evidence pack (Data Gap DG002). Based on known pharmacology, nitrous oxide acts primarily as an NMDA-receptor antagonist and mild anesthetic/analgesic gas — a mechanism with no established link to the α1-adrenergic smooth-muscle tone or DHT/5α-reductase-driven glandular hyperplasia pathways that underlie BPH pathophysiology.

The evidence pack's own repurposing rationale is explicit that this high TxGNN score (99.52%) most likely reflects a **confounded knowledge-graph signal**: nitrous oxide co-occurs frequently in urology/prostate-procedure literature (as an anesthetic used *during* prostate biopsies, cryotherapy, and prostatectomies) rather than being used *to treat* BPH itself. In other words, the model appears to have learned "nitrous oxide is associated with prostate procedures," not "nitrous oxide treats prostate enlargement."

Given the absence of MOA data supporting a plausible biological pathway, and the model's own annotation that this is likely a spurious co-occurrence signal, the mechanistic case for repurposing is weak.

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT05803096](https://clinicaltrials.gov/study/NCT05803096) | Phase 4 | Completed | 143 | Evaluated self-administered nitrous oxide during transrectal prostate biopsy to reduce patient anxiety/pain. This is a procedural sedation/anxiolysis study, not a trial of nitrous oxide as BPH treatment — no BPH efficacy endpoints (prostate volume, uroflow, IPSS) were assessed. Rated low direct relevance (Grade C). |

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [9223887](https://pubmed.ncbi.nlm.nih.gov/9223887/) | 1997 | Case report | Masui (Jpn J Anesthesiology) | Anesthetic management (including inhalational agents) for a patient with pure autonomic failure undergoing suprapubic prostatectomy — an anesthesia case report, not a BPH-treatment study. |
| [4108916](https://pubmed.ncbi.nlm.nih.gov/4108916/) | 1971 | Case report | Zeitschrift für praktische Anästhesie und Wiederbelebung | Describes combination anesthesia (methohexital-based) in high-risk urologic patients; nitrous oxide appears as part of the anesthetic regimen, not as a BPH therapy. |
| [4171323](https://pubmed.ncbi.nlm.nih.gov/4171323/) | 1968 | Other (technical/device report) | International Surgery | Describes a new apparatus for cryotherapy of prostate obstruction; nitrous oxide's role here is likely as a cryogen/refrigerant in the device, not a pharmacological treatment. |

## Malaysia Market Information

Malaysia (NPRA) shows nitrous oxide as marketed with **5 active registrations**; however, the individual license numbers, product names, dosage forms, and approved indication texts were not returned in this evidence pull and cannot be tabulated at this time.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted BPH indication is not supported by a plausible mechanism, and all available "evidence" (the one trial and all three publications) concerns nitrous oxide's use as a procedural anesthetic/analgesic during prostate interventions — not as a treatment for BPH itself. The evidence pack itself flags this as a likely confounded knowledge-graph signal (L5, decision stage S0).

**To proceed, the following is needed:**
- NPRA package insert warnings, contraindications, and drug interaction data (blocking gap, DG001) — required before any safety pre-assessment can begin
- Verified mechanism of action data (DG002) to assess biological plausibility
- If this hypothesis is still pursued, dedicated studies evaluating nitrous oxide against BPH-specific endpoints (prostate volume, uroflowmetry, IPSS) rather than incidental procedural-anesthesia use
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

